Clinical Trial Update: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Pepinemab was studied in a pediatric Phase 1/2 trial for recurrent, relapsed, or refractory solid tumors, including osteosarcoma. Results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Pepinemab (pepinemab)

Snippet

Sponsor: Children's Oncology Group | Conditions: Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-26